PD-L1/PD-1 Inhibitors Plus Chemotherapy Versus Chemotherapy Alone for the Neoadjuvant Treatment of Limited-stage SCLC

NCT06375109 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

60

Enrollment

OTHER

Sponsor class

Conditions

Limited-stage Small-cell Lung Cancer

Interventions

DRUG: Tislelizumab
DRUG: Carboplatin injection
DRUG: Cisplatin injection
DRUG: Etoposide injection

Sponsor

Beijing Chest Hospital, Capital Medical University